Cosmos Health reports preliminary $54.3 million nine-month revenue

• Cosmos Health reported preliminary nine-month revenue of approximately $54.3 million, marking a 19% increase over the same period in 2025.
• Following the preliminary financial revenue update, the company's share price traded around $0.32.
• The company reaffirmed its expected 2026 revenue of over $90 million, anticipating its highest-ever fourth-quarter performance.

Cosmos Health (NASDAQ:COSM) reported preliminary nine-month revenue of approximately $54.3 million for the period ended September 30, 2026.

The 19% year-over-year revenue increase built upon the $45.6 million recorded in 2025, sitting 35% above the levels achieved in 2024.

Preliminary third-quarter revenue reached approximately $17.4 million, representing a 2% gain over 2025 and a 40% jump compared to 2024.

The company noted that every single quarter of 2026 has successfully exceeded its respective historical corresponding-quarter revenue record.

Following the preliminary financial announcement, the Cosmos Health share price traded at $0.32.

Operational drivers included Cana Laboratories pushing its production pipeline past 32.7 million units alongside peak distribution volumes at CosmoFarm.

Management reaffirmed its full-year 2026 revenue target of over $90 million—representing roughly 38% growth over 2025—backed by expectations for a record-breaking fourth quarter.